Jessica A. Miller, Patricia A. Thompson, Iman A. Hakim, Ana Maria Lopez, Cynthia A. Thomson, Wade Chew, Chiu-Hsieh Hsu, H.-H. Sherry Chow Mel & Enid Zuckerman College ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks larger ones without side effects. Named ErSo-TFPy, this drug shows ...

The response of ER+/HER2– breast cancer to treatment varies widely, which not only affects clinical outcomes but can pose a challenge to the effective medical management of the condition.

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...

Jan. 22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone ...

The company emphasizes its commitment to providing safer and more tolerable treatment options for breast cancer patients. With analyst price targets ranging from $4 to $7 per share and an overall ...

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.